| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5712279 | CHIESI | Inhibitors of microsomal triglyceride transfer protein and method |
Feb, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5712279 | CHIESI | Inhibitors of microsomal triglyceride transfer protein and method |
Feb, 2015
(9 years ago) | |
| US5739135 | CHIESI | Inhibitors of microsomal triglyceride transfer protein and method |
Apr, 2015
(9 years ago) | |
| US6492365 | CHIESI | Microsomal triglyceride transfer protein |
Dec, 2019
(4 years ago) | |
| US10555938 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(10 months from now) | |
| US8618135 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(10 months from now) | |
| US9364470 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(10 months from now) | |
| US9265758 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(10 months from now) | |
| US9433617 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(10 months from now) | |
| US9861622 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
Mar, 2025
(10 months from now) | |
| US10016404 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(10 months from now) | |
| US7932268 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Aug, 2027
(3 years from now) | |
Juxtapid is owned by Chiesi.
Juxtapid contains Lomitapide Mesylate.
Juxtapid has a total of 12 drug patents out of which 4 drug patents have expired.
Expired drug patents of Juxtapid are:
- US5712279
- US5739135
- US6492365
- US5712279
Juxtapid was authorised for market use on 21 December, 2012.
Juxtapid is available in capsule;oral dosage forms.
Juxtapid can be used as a dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses, treatment of hypercholesterolemia, hyperlipidemia and hyperlipoproteinemia in patients with homozygous familial hypercholesterolemia, a dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses, treatment of hypercholesterolemia by decreasing the amount or activity of microsomal triglyceride transfer protein in patients with homozygous familial hypercholesterolemia.
Drug patent challenges can be filed against Juxtapid from 21 December, 2016.
The generics of Juxtapid are possible to be released after 19 August, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2017 |
| Orphan Drug Exclusivity(ODE-36) | Dec 21, 2019 |
Drugs and Companies using LOMITAPIDE MESYLATE ingredient
NCE-1 date: 21 December, 2016
Market Authorisation Date: 21 December, 2012
Treatment: Treatment of hypercholesterolemia, hyperlipidemia and hyperlipoproteinemia in patients with homozygous familial hypercholesterolemia; Treatment of hypercholesterolemia by decreasing the amount or acti...
Dosage: CAPSULE;ORAL
JUXTAPID family patents
